VIMG.F Stock Overview
Vimian Group AB (publ) engages in the animal health business worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Vimian Group AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr2.45 |
| 52 Week High | kr3.85 |
| 52 Week Low | kr2.25 |
| Beta | 1.52 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -32.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| VIMG.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 1.0% |
| 1Y | n/a | -1.4% | 21.9% |
Return vs Industry: Insufficient data to determine how VIMG.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how VIMG.F performed against the US Market.
Price Volatility
| VIMG.F volatility | |
|---|---|
| VIMG.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VIMG.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine VIMG.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 1,000 | Patrik Eriksson | vimian.com |
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.
Vimian Group AB (publ) Fundamentals Summary
| VIMG.F fundamental statistics | |
|---|---|
| Market cap | US$1.61b |
| Earnings (TTM) | US$10.66m |
| Revenue (TTM) | US$359.48m |
151.0x
P/E Ratio4.5x
P/S RatioIs VIMG.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIMG.F income statement (TTM) | |
|---|---|
| Revenue | €331.73m |
| Cost of Revenue | €102.30m |
| Gross Profit | €229.43m |
| Other Expenses | €219.59m |
| Earnings | €9.84m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 10, 2024
| Earnings per share (EPS) | 0.019 |
| Gross Margin | 69.16% |
| Net Profit Margin | 2.97% |
| Debt/Equity Ratio | 57.4% |
How did VIMG.F perform over the long term?
See historical performance and comparison